Recruiting
Phase 1
Phase 2

A Phase I/IIa Study of AZD8205 Given Alone or in Combination With Anticancer Drugs, in Participants With Advanced or Metastatic Solid Malignancies

Sponsor:

AstraZeneca

Code:

NCT05123482

Conditions

Breast Cancer

Biliary Tract Carcinoma

Ovarian Cancer

Endometrial Cancer

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

AZD8205

AZD8205 and AZD2936 (Rilvegostomig)

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information